Procedures
Coma, Stroke
ADVERSE EVENT, COMA, STROKE
Patients allocated to eculizumab treatment, received intravenous infusion with eculizumab 1200 mg at three time points: <12 h, on day 3, and day 7 after ictus. Eculizumab infusions were prepared according to the instructions of the manufacturer.Study procedures included daily Glasgow Coma Scale evaluations; serum withdrawal on multiple days (day 1 (before the first eculizumab administration), day 2, day 4, day 6, day 9, day 12, and day 14); CSF withdrawal on day 3 (before the second eculizumab administration), National Institutes of Health Stroke Scale (NIHSS), and World Federation of Neurosurgical Societies (WFNS) scores and a brain magnetic resonance imaging (MRI) scan 2 weeks after ictus; (serious) adverse event ((S)AE) recording up to 4 weeks after ictus, and a(n) (S)AE questionnaire 4 weeks after ictus; Montreal Cognitive Assessment (MoCA) and quality of life assessment (EQ-5D-5L) in the outpatient clinic 10 weeks after ictus; and a mRS score 13 weeks after ictus. CSF was obtained by either lumbar puncture or sampling from an external lumbar or ventricular CSF drain. Serum and CSF sampling, processing, and storage are described in the 